Drug Sponsors

Wright Medical Group, Tornier to merge

Wednesday, October 29, 2014 01:29 PM

Wright Medical Group, a specialty orthopedic company that provides extremity and biologic solutions, and Tornier, a global medical device company, have entered a definitive merger agreement under which Wright and Tornier will combine in an all-stock transaction with a combined equity value of approximately $3.3 billion.

More... »


Amgen outlines strategy, will cut up to 4,000 jobs

Wednesday, October 29, 2014 01:28 PM

Amgen has outlined the company's strategy, growth objectives and capital allocation plans, and provided financial guidance for 2015. In addition to the approximately 2,900 positions already set to be eliminated by the end of 2015, an additional 600 to 1,100 jobs will be cut.

More... »


SRI International opens clinical trial unit in Michigan

Monday, October 27, 2014 01:04 PM

SRI Biosciences, a division of SRI International, a California-based independent nonprofit research institute, has completed construction of an early-phase clinical trial facility in Plymouth, Mich. The 9,400-square-foot unit, located in the Michigan Life Science Innovation Center, now is open and fully equipped for early-stage human research studies of new medicines and medical devices. 

More... »

Report: 10 men for every woman present in biotech boardrooms

Monday, October 27, 2014 12:57 PM

The biotechnology sector is considerably under represented by female executives and board directors, according to a new report by Liftstream, a U.K.-based company providing executive recruitment services to the biotechnology sector. The gender diversity report, Diversifying the Outlook—The X&Y of Biotechnology Leadership, is a detailed analysis of women leaders in European and U.S. biotech companies.

More... »

Lilly, Zymeworks expand collaboration agreement

Friday, October 24, 2014 01:10 PM

Eli Lilly and Zymeworks, a Vancouver-based, privately held biotherapeutics company, are expanding an existing licensing and collaboration agreement. Originally announced in January, the global strategic collaboration is focused on the development of an undisclosed number of novel bi-specific antibody therapeutics using Zymeworks' proprietary Azymetric platform.

More... »

Celgene collaborates with Sutro Biopharma, inks option to acquire

Friday, October 24, 2014 01:09 PM

Sutro Biopharma, located in South San Francisco, has entered into a strategic collaboration and option agreement with Celgene to discover and develop multispecific antibodies and antibody drug conjugates (ADCs). This new agreement follows the December 2012 collaboration between the two companies and focuses on the field of immuno-oncology, while further broadening the Sutro platform for discovery, development and manufacture of best-in-class biotherapeutics.

More... »

J&J Innovation adds J-Labs incubator at Texas Medical Center

Friday, October 24, 2014 01:07 PM

Johnson & Johnson Innovation plans to expand J-Labs (formerly Janssen Labs) to include a new incubator located within Texas Medical Center's new Innovation Institute. The 30,000-square-foot J-Labs facility will accommodate up to 50 life science startups.

More... »

Treasury’s tax inversion changes scuttle some big biopharma mergers, modify others, prompting calls for Congressional corporate tax reform

Thursday, October 23, 2014 03:50 PM

By Ronald Rosenberg
CenterWatch Staff Writer

The widely-discussed $54.6 billion acquisition of Dublin-based Shire by AbbVie is officially canceled, having crumbled after a notice by the U.S. Treasury Department to tighten tax rules that deter U.S. companies from moving their legal headquarters to countries with lower business taxes.

More... »

Roche invests in its Switzerland site

Thursday, October 23, 2014 01:23 PM

Roche has presented development plans for its Basel, Switzerland site. Over the next 10 years, Roche will invest $3.1 billion in the construction of a new R&D center for around 1,900 employees, a state-of-the-art office building for up to 1,700 employees.

More... »

Actavis signs option to acquire Rhythm subsidiary

Thursday, October 23, 2014 01:08 PM

Actavis, a Dublin, Ireland-based global specialty pharmaceutical company, has been granted an exclusive option to acquire Rhythm subsidiary Rhythm Health, a Boston, Mass.-based biopharmaceutical company developing relamorelin (RM-131), a peptide ghrelin agonist, for the treatment of diabetic gastroparesis and other GI functional disorders.

More... »

CenterWatch
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs